icon- folder.gif   Conference Reports for NATAP  
 
  Back grey_arrow_rt.gif
 
 
 
 
 
Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR)
 
 
  Esteban Martinez, Hospital Clinic
 
Reported by Jules Levin

0710201

0710202